Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy

Journal of Lipid Research

Volumn 54, Issue 7, 2013, Pages 1980-1987

  Brautbar, Ariel ^a,b,c   Barbalic, Maja ^d   Chen, Fengju ^d   Belmont, John ^b   Virani, Salim S ^b,c,e   Scherer, Steve ^b   Hegele, Robert A ^f   Ballantyne, Christie M ^b,c  

^a MARSHFIELD CLINIC   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Apolipoproteins; Cholesterol lowering drugs; Fenofibric acid; High density lipoprotein; Lipidsrare variants

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A5; ATORVASTATIN; FENOFIBRIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

3' UNTRANSLATED REGION; APOA5 GENE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DYSLIPIDEMIA; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; INTRON; LOW DRUG DOSE; MISSENSE MUTATION; MONOTHERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; REGULATOR GENE; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

APOLIPOPROTEINS; CHOLESTEROL-LOWERING DRUGS; FENOFIBRIC ACID; HIGH DENSITY LIPOPROTEIN; LIPIDS; RARE VARIANTS;

AMINO ACIDS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS A; CHOLESTEROL, HDL; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; GENETIC VARIATION; HUMANS; MALE; PROMOTER REGIONS, GENETIC; TRIGLYCERIDES;

EID: 84878959605     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M034132     Document Type: Article

References (29)

1. Kathiresan, S., C. J. Willer, G. M. Peloso, S. Demissie, K. Musunuru, E. E. Schadt, L. Kaplan, B. Bennett, Y. Li, T. Tanaka, et al. 2009. Common variants at 30 loci contribute to polygenic dyslipidemia. Nat. Genet. 41: 56-65.
2. Teslovich, T. M., K. Musunuru, A. V. Smith, A. C. Edmondson, I. M. Stylianou, M. Koseki, J. P. Pirruccello, S. Ripatti, D. I. Chasman, C. J. Willer, et al. 2010. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 466: 707-713.
3. Johansen, C. T., J. Wang, M. B. Lanktree, H. Cao, A. D. McIntyre, M. R. Ban, R. A. Martins, B. A. Kennedy, R. G. Hassell, M. E. Visser, et al. 2010. Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat. Genet. 42: 684-687.
4. Vergeer, M., S. J. Korporaal, R. Franssen, I. Meurs, R. Out, G. K. Hovingh, M. Hoekstra, J. A. Sierts, G. M. Dallinga-Thie, M. M. Motazacker, et al. 2011. Genetic variant of the scavenger receptor BI in humans. N. Engl. J. Med. 364: 136-145.
5. Birjmohun, R. S., B. A. Hutten, J. J. Kastelein, and E. S. Stroes. 2005. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 45: 185-197. (Pubitemid 40094724)
6. Farnier, M., M. W. Freeman, G. Macdonell, I. Perevozskaya, M. J. Davies, Y. B. Mitchel, and B. Gumbiner; and Ezetimibe Study Group. 2005. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J. 26: 897-905. (Pubitemid 40676570)
7. Farnier, M., E. Roth, B. Gil-Extremera, G. F. Mendez, G. Macdonell, C. Hamlin, I. Perevozskaya, M.J. Davies, D. Kush, Y.B. Mitchel; and Ezetimibe/Simvastatin + Fenofibrate Study Group. 2007. Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am. Heart J. 153: 335.e1-335.e8.
8. Staels, B., J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J. C. Fruchart. 1998. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 98: 2088-2093. (Pubitemid 28512236)
9. Garelnabi, M., K. Lor, J. Jin, F. Chai, and N. Santanam. 2013. The paradox of ApoA5 modulcation of triglycerides: evidence from clinical and basic research. Clin. Biochem. 46: 12-19.
10. Brautbar, A., D. Covarrubias, J. Belmont, F. Lara-Garduno, S. S. Virani, P. H. Jones, S. M. Leal, and C. M. Ballantyne. 2011. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 219: 737-742.
11. Lai, C. Q., D. K. Arnett, D. Corella, R. J. Straka, M. Y. Tsai, J. M. Peacock, X. Adiconis, L. D. Parnell, J. E. Hixson, M. A. Province, et al. 2007. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler. Thromb. Vasc. Biol. 27: 1417-1425. (Pubitemid 46809433)
12. Brautbar, A., S. S. Virani, J. Belmont, V. Nambi, P. H. Jones, and C. M. Ballantyne. 2012. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. J. Lipid Res. 53: 556-560.
13. Ma, L., C. M. Ballantyne, J. W. Belmont, A. Keinan, and A. Brautbar. 2012. Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibit apolipoprotein B reduction following statin-fenofibric acid therapy in individuals with mixed dyslipidemia. J. Lipid Res. 53: 2425-2428.
14. Jones, P. H., H. E. Bays, M. H. Davidson, M. T. Kelly, S. M. Buttler, C. M. Setze, D. J. Sleep, and J. C. Stolzenbach. 2008. Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins: study design and rationale of a phase III clinical programme. Clin. Drug Investig. 28: 625-634.
15. Zhang, J., D. A. Wheeler, I. Yakub, S. Wie, R. Sood, W. Rowe, P. P. Liu, R. A. Gibbs, and K. H. Buetow. 2005. SNPdetector: a software tool for sensitive and accurate SNP detection. PLOS Comput. Biol. 1: e53.
16. Li, B., and S. M. Leal. 2008. Methods for detecting associations with rare variants for common diseases: application to analysis of sequence data. Am. J. Hum. Genet. 83: 311-321.
17. Price, A. L., G. V. Kryukov, P. I. de Bakker, S. M. Purcell, J. Staples, L. J. Wei, and S. R. Sunyaev. 2010. Pooled association tests for rare variants in exon-resequencing studies. Am. J. Hum. Genet. 86: 832-838.
18. Madsen, B. E., and S. R. Browning. 2009. A groupwise association test for rare mutations using a weighted sum statistic. PLoS Genet. 5: e1000384.
19. Vu-Dac, N., P. Gervois, H. Jakel, M. Nowak, E. Bauge, H. Dehondt, B. Staels, L. A. Pennacchio, E. M. Rubin, J. Fruchart-Najib, et al. 2003. Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor a activators. J. Biol. Chem. 278: 17982-17985. (Pubitemid 36799406)
20. Talmud, P. J., J. Palmen, W. Putt, L. Lins, and S. E. Humphries. 2005. Determination of the functionality of common APOA5 polymorphisms. J. Biol. Chem. 280: 28215-28220. (Pubitemid 41105717)
21. Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration, Sarwar, N., M. S. Sandhu, S. L. Ricketts, A. S. Butterworth, E. Di Angelantonio, S. M. Boekholdt, W. Ouwehand, H. Watkins, N. J. Samari, D. Saleheen, et al. 2010. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet. 375: 1634-1639. [Erratum. 2010. Lancet. 376: 90.]
22. De Caterina, R., P.J. Talmud, P.A. Merlini, L. Foco, R. Pastorino, D. Altshuler, F. Mauri, F. Peyvandi, D. Lina, S. Kathiresan, L. Bernardinelli, D. Ardissino, and Gruppo Italiano Aterosclerosi. 2011. Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction. Atherosclerosis. 214: 397-403.
23. Cardona, F., M. Guardiola, M. I. Queipo-Ortuno, M. Murri, J. Ribalta, and F. J. Tinahones. 2009. The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study. Atherosclerosis. 206: 148-152.
24. Frick, M. H., O. Elo, K. Haapa, O. P. Heinonen, P. Heinsalmi, P. Helo, J. K. Huttunen, P. Kaitaniemi, P. Koskinen, V. Manninen, et al. 1987. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N. Engl. J. Med. 317: 1237-1245. (Pubitemid 17147964)
25. Rubins, H. B., S. J. Robins, D. Collins, C. L. Fye, J. W. Anderson, M. B. Elam, F. H. Faas, E. Linares, E. J. Schaefer, G. Schectman, et al. 1999. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341: 410-418. (Pubitemid 29362514)
26. Keech, A., R. J. Simes, P. Barter, J. Best, R. Scott, M. R. Taskinen, P. Forder, A. Pillai, T. Davis, P. Glasziou, P. Drury, Y. A. Kesäniemi, D. Sullivan, D. Hunt, P. Colman, M. d'Emden, M. Whiting, C. Ehnholm, M. Laakso, and FIELD study investigators. 2005. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 366: 1849-1861.
27. van Raalte, D. H., M. Li, P. H. Pritchard, and K. M. Wasan. 2004. Peroxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological target with a promising future. Pharm. Res. 21: 1531-1538. (Pubitemid 41184380)
28. Tóth, P. P., D. Potter, and E. E. Ming. 2012. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J. Clin. Lipidol. 6: 325-330.
29. Liu, Y., J. M. Ordovas, G. Gao, M. Province, R. J. Straka, M. Y. Tsai, C. Q. Lai, K. Zhang, I. Borecki, J. E. Hixson, et al. 2009. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipidlowering drugs and diet network study. Pharmacogenet. Genomics. 19: 161-169.